BioSyent Inc. (TSXV:RX) is the Subject of StockPotentials Report by eResearch Corp - Video Summary of Report Posted on www.investmentpitch.com
(Thomson Reuters ONE) -
Vancouver, British Columbia, April 16, 2012 - Toronto based eResearch has issued
a StockPotentials report on BioSyent Inc. (TSXV:RX). StockPotentials reports
cover smaller companies that have little or no following on the Street, that
eResearch believes would be primarily of interest to retail investors.
InvestmentPitch.com has produced a "video news alert" based on this report. If
this link is not enabled, please visit www.investmentpitch.com and enter
"BioSyent" in the search box.
BioSyent is a specialty pharmaceutical company whose wholly owned subsidiary,
BioSyent Pharma, licenses medicines that have been successfully developed and do
not require further research and development spending other than regulatory
costs. The company manages these drug candidates through the regulatory process
and approval, and once approved, it markets these products in Canada. The
company is focused on both branded and generic medications that occupy a
distinct niche in the market, with significant entry barriers.
One of the company's products is FeraMAX, an oral iron supplement, which has
been developed to reduce the common side effects often associated with certain
other iron supplements.
The company's other wholly owned subsidiary, Hedley Technologies, operates the
company's legacy business manufacturing and marketing a food-safe grain
insecticide: Protect-It. This insecticide is used as a preventative treatment
against insect infestations in stored grains.
The company has aggressively expanded its sales force over the past 12 months to
build a solid on-the-ground presence throughout Canada. Revenue for 2011
increased 67% to $2.8 million, driven by the pharmaceutical division and FeraMAX
sales, which grew 203%, and now accounts for 73% of total revenue compared to
40% in 2010. Strong revenue and profitability growth in 2011 propelled the
company into the 2012 TSX Venture Top 50 companies. The company is ranked 5th in
the list of 10 leading Technology and Life Sciences companies for 2011.
eResearch cautions the company could face intense competition from larger and
established players.
BioSyent is trading at $0.57, and with approximately 13 million shares
outstanding, is capitalized at $7 million.
For more information about BioSyent please visit their website at
www.biosyent.com or call 905-206-0013 or email info(at)biosyent.com.
For a copy of the report, contact eResearch at www.eresearch.ca. While on their
site, sign up for their free reports. eResearch does not receive a fee for the
preparation and publication of StockPotentials reports.
InvestmentPitch.com, a multimedia company that provides a combined solution for
creating and hosting financial video content, and distributing it across
multiple platforms to investors and financial professionals, specializes in
producing short three minute videos based on significant news releases and
research reports.
CONTACT:
InvestmentPitch.com
Barry Morgan, CFO
604-684-5524
bmorgan(at)investmentpitch.com
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: InvestmentPitch via Thomson Reuters ONE
[HUG#1602974]
Unternehmensinformation / Kurzprofil:
Datum: 16.04.2012 - 23:33 Uhr
Sprache: Deutsch
News-ID 135540
Anzahl Zeichen: 3895
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 149 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"BioSyent Inc. (TSXV:RX) is the Subject of StockPotentials Report by eResearch Corp - Video Summary of Report Posted on www.investmentpitch.com"
steht unter der journalistisch-redaktionellen Verantwortung von
InvestmentPitch (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
